Baxter International Inc. (BAX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative se...
Baxter International Inc.'s revenue increased 5.7% year over year, from $10.64B to $11.24B.
Net income decreased 47.5% over the same period, from $-649.0M to $-957.0M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 11% in total.
Total debt decreased by 100.0% to $1.0M.
The debt-to-equity ratio stands at 0.00, indicating a conservative leverage profile.
Operating cash flow declined 17.1% to $845.0M.
Baxter International Inc. maintains a negative net profit margin of -8.5%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $479.0M-87.4% | $140.0M | $207.0M | $-82.0M | $253.0M | $26.68B | $12.94B | $7.87B |
| Q4 FY2024 | $2.75B+474.7% | $-512.0M | $959.0M | $439.0M | $488.0M | $25.78B | $12.50B | $6.96B |
| Q1 FY2025 | $2.63B-4.6% | $126.0M | $861.0M | $262.0M | $-193.0M | $21.30B | $11.0M | $7.08B |
| Q2 FY2025 | $2.81B+7.0% | $91.0M | $991.0M | $434.0M | $217.0M | $21.05B | $6.0M | $7.32B |
| Q3 FY2025 | $2.83B+0.9% | $-46.0M | $950.0M | $287.0M | $237.0M | $21.07B | $4.0M | $7.24B |
| Q4 FY2025 | $2.97B+4.9% | $-1.13B | $577.0M | $54.0M | $584.0M | $20.05B | $1.0M | $6.13B |
| Q1 FY2026 | $2.70B-9.2% | $-15.0M | $891.0M | $163.0M | $213.0M | $19.85B | $9.69B | $6.02B |
| Q2 FY2026 | $2.96B+9.6% | $126.0M | $1.03B | $427.0M | $285.0M | $19.79B | $9.67B | $6.18B |
Balance Sheet Summary (Q2 FY2026)
Baxter International Inc. (BAX) Financial Statements & Revenue History
Baxter International Inc. (BAX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $25.30 with a market capitalization of $13. This page provides 42 historical financial statements for Baxter International Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Baxter International Inc. reported revenue of $11.2 billion, representing 5.7% year-over-year growth. The net profit margin of -8.5% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.00 shows conservative leverage.
BAX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Baxter International Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BAX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BAX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Baxter International Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BAX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BAX Financial Data
Investors use Baxter International Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BAX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BAX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BAX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Baxter International Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BAX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.